EPSTEIN ROBERT S 4

What Happened

• Robert S. Epstein, a director of Fate Therapeutics (FATE), exercised stock options on May 5, 2026 to acquire a total of 50,000 shares. The filing shows 25,000 shares acquired at $1.69 per share (cash paid $42,250) and 25,000 shares recorded at $0 (listed as a derivative conversion). Both transactions are reported as code "M" (option exercise/conversion).

Key Details

• Transaction date: 2026-05-05; Filing date: 2026-05-06 (filed the next day).
• Prices/amounts: 25,000 shares @ $1.69 = $42,250; 25,000 shares @ $0 = $0 (derivative conversion).
• Shares owned after transaction: not specified in the filing.
• Footnote: F1 states the optioned shares vested and became exercisable at the 2017 Annual Meeting of Stockholders.
• Transaction code: M = exercise/conversion of derivative (option).

Context

• This was an exercise of previously granted options, not an open-market purchase or a sale; the filing does not indicate any immediate sale of the shares (no cashless sale reported).
• Option exercises can be routine (vesting-related) and do not necessarily reflect a change in sentiment; the filing confirms these options vested long ago (2017).